ICT1 knockdown inhibits breast cancer cell growth via induction of cell cycle arrest and apoptosis

Wang,Chen; Liang,Chenlu; Feng,Weiliang; Xia,Xianghou; Chen,Feng; Qiao,Enqi; Zhang,Xiping; Chen,Daobao; Ling,Zhiqiang; Yang,Hongjian

doi:10.3892/ijmm.2017.2913

ICT1 knockdown inhibits breast cancer cell growth via induction of cell cycle arrest and apoptosis

Authors:
- Chen Wang
- Chenlu Liang
- Weiliang Feng
- Xianghou Xia
- Feng Chen
- Enqi Qiao
- Xiping Zhang
- Daobao Chen
- Zhiqiang Ling
- Hongjian Yang
View Affiliations

Affiliations: Department of Oncology, First Clinical Medical College, Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: March 9, 2017 https://doi.org/10.3892/ijmm.2017.2913
Pages: 1037-1045

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The protein encoded by immature colon carcinoma transcript 1 (ICT1) is a component of the human mitochondrial ribosome, and is reported to be implicated in cell proliferation, viability and apoptosis of HeLa cells. This study was conducted to investigate the role of ICT1 in human breast cancer. Oncomine database was used to investigate ICT1 expression in human breast cancer tissues compared to normal tissues. The results showed that ICT1 was highly overexpressed in various human breast cancer subtypes. Then short hairpin RNA (shRNA)-mediated knockdown of ICT1 was performed in human breast cancer ZR-75-30 and T-47D cells. A series of functional analysis, including MTT, colony formation and flow cytometry assays were conducted after ICT1 knockdown. Our results demonstrated that knockdown of ICT1 significantly suppressed cell viability and proliferation through cell cycle arrest at the G2/M phase and induced apoptosis in breast cancer cells. Furthermore, knockdown of ICT1 altered signaling pathways associated with cell growth and apoptosis, including phospho‑BAD (Ser112), phospho-PRAS40 (Thr246) and induction of phospho‑AMPKα (Thr172). Additionally, it was further confirmed by western blot analysis that ICT1 knockdown altered the expression of apoptosis- or cell cycle‑related proteins such as Bcl-2, caspase-3, CDK1, CDK2 and cyclin B. In conclusion, targeting ICT1 in breast cancer cells may provide a new strategy for breast cancer gene therapy.

View Figures

View References

1	Ferlay J, Héry C, Autier P and Sankaranarayanan R: Global burden of breast cancer. Breast Cancer Epidemiology. Li C: Springer; New York: pp. 1–19. 2010, View Article : Google Scholar
2	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
3	Key T, Appleby P, Barnes I, Reeves G and Endogenous H; Endogenous Hormones and Breast Cancer Collaborative Group: Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst. 94:606–616. 2002. View Article : Google Scholar : PubMed/NCBI
4	Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K and Detmar M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 7:192–198. 2001. View Article : Google Scholar : PubMed/NCBI
5	Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:50–56. 2001. View Article : Google Scholar : PubMed/NCBI
6	Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, et al Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet. 366:2087–2106. 2005. View Article : Google Scholar : PubMed/NCBI
7	Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
8	Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V, et al: In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol. 161:290–297. 2010.PubMed/NCBI
9	Das S, Ferlito M, Kent OA, Fox-Talbot K, Wang R, Liu D, Raghavachari N, Yang Y, Wheelan SJ, Murphy E, et al: Nuclear miRNA regulates the mitochondrial genome in the heart. Circ Res. 110:1596–1603. 2012. View Article : Google Scholar : PubMed/NCBI
10	Dames S, Eilbeck K and Mao R: A high-throughput next-generation sequencing assay for the mitochondrial genome. Methods Mol Biol. 1264:77–88. 2015. View Article : Google Scholar : PubMed/NCBI
11	Handa Y, Inaho N and Nameki N: YaeJ is a novel ribosome-associated protein in Escherichia coli that can hydrolyze peptidyl-tRNA on stalled ribosomes. Nucleic Acids Res. 39:1739–1748. 2011. View Article : Google Scholar
12	Akabane S, Ueda T, Nierhaus KH and Takeuchi N: Ribosome rescue and translation termination at non-standard stop codons by ICT1 in mammalian mitochondria. PLoS Genet. 10:e10046162014. View Article : Google Scholar : PubMed/NCBI
13	Richter R, Rorbach J, Pajak A, Smith PM, Wessels HJ, Huynen MA, Smeitink JA, Lightowlers RN and Chrzanowska-Lightowlers ZM: A functional peptidyl-tRNA hydrolase, ICT1, has been recruited into the human mitochondrial ribosome. EMBO J. 29:1116–1125. 2010. View Article : Google Scholar : PubMed/NCBI
14	Handa Y, Hikawa Y, Tochio N, Kogure H, Inoue M, Koshiba S, Güntert P, Inoue Y, Kigawa T, Yokoyama S, et al: Solution structure of the catalytic domain of the mitochondrial protein ICT1 that is essential for cell vitality. J Mol Biol. 404:260–273. 2010. View Article : Google Scholar : PubMed/NCBI
15	Kogure H, Handa Y, Nagata M, Kanai N, Güntert P, Kubota K and Nameki N: Identification of residues required for stalled-ribosome rescue in the codon-independent release factor YaeJ. Nucleic Acids Res. 42:3152–3163. 2014. View Article : Google Scholar :
16	Xie R, Zhang Y, Shen C, Cao X, Gu S and Che X: Knockdown of immature colon carcinoma transcript-1 inhibits proliferation of glioblastoma multiforme cells through Gap 2/mitotic phase arrest. Onco Targets Ther. 8:1119–1127. 2015.PubMed/NCBI
17	Sparrow JR and Cai B: Blue light-induced apoptosis of A2E-containing RPE: Involvement of caspase-3 and protection by Bcl-2. Invest Ophthalmol Vis Sci. 42:1356–1362. 2001.PubMed/NCBI
18	Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX and Shao JY: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 14:2348–2360. 2008. View Article : Google Scholar : PubMed/NCBI
19	Wang Z, Xu D, Gao Y, Liu Y, Ren J, Yao Y, Yin L, Chen J, Gan S and Cui X: Immature colon carcinoma transcript 1 is essential for prostate cancer cell viability and proliferation. Cancer Biother Radiopharm. 30:278–284. 2015. View Article : Google Scholar : PubMed/NCBI
20	Lao X, Feng Q, He G, Ji M, Zhu D, Xu P, Tang W, Xu J and Qin X: Immature colon carcinoma transcript-1 (ICT1) expression correlates with unfavorable prognosis and survival in patients with colorectal cancer. Ann Surg Oncol. 23:3924–3933. 2016. View Article : Google Scholar : PubMed/NCBI
21	Wang Y, He J, Zhang S, Yang Q, Wang B, Liu Z and Wu X: Knockdown of immature colon carcinoma transcript-1 inhibits proliferation and promotes apoptosis of non-small cell lung cancer cells. Technol Cancer Res Treat. Jul 13–2016.(Epub ahead of print). doi:20161533034616657977. View Article : Google Scholar
22	Arellano M and Moreno S: Regulation of CDK/cyclin complexes during the cell cycle. Int J Biochem Cell Biol. 29:559–573. 1997. View Article : Google Scholar : PubMed/NCBI
23	Ji YB, Wu D, Dai QC, Guo L and Chen N: The research on the medicinal value of Amaryllidaceae plants. Appl Mech Mater. 411–414:3223–3226. 2013. View Article : Google Scholar
24	Cmielová J and Rezáčová M: p21^Cip1/Waf1 protein and its function based on a subcellular localization [corrected]. J Cell Biochem. 112:3502–3506. 2011. View Article : Google Scholar
25	Caputi M, Russo G, Esposito V, Mancini A and Giordano A: Role of cell-cycle regulators in lung cancer. J Cell Physiol. 205:319–327. 2005. View Article : Google Scholar : PubMed/NCBI
26	Lim S and Kaldis P: Cdks, cyclins and CKIs: Roles beyond cell cycle regulation. Development. 140:3079–3093. 2013. View Article : Google Scholar : PubMed/NCBI
27	Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR and Witters LA: The Ca²⁺/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem. 280:29060–29066. 2005. View Article : Google Scholar : PubMed/NCBI
28	Morgensztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 16:797–803. 2005. View Article : Google Scholar : PubMed/NCBI
29	Garcia-Haro L, Garcia-Gimeno MA, Neumann D, Beullens M, Bollen M and Sanz P: Glucose-dependent regulation of AMP-activated protein kinase in MIN6 beta cells is not affected by the protein kinase A pathway. FEBS Lett. 586:4241–4247. 2012. View Article : Google Scholar : PubMed/NCBI
30	Xu J, Zhang T, Wang T, You L and Zhao Y: PIM kinases: An overview in tumors and recent advances in pancreatic cancer. Future Oncol. 10:865–876. 2014. View Article : Google Scholar : PubMed/NCBI
31	Meisse D, Van de Casteele M, Beauloye C, Hainault I, Kefas BA, Rider MH, Foufelle F and Hue L: Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett. 526:38–42. 2002. View Article : Google Scholar : PubMed/NCBI
32	Shao JJ, Zhang AP, Qin W, Zheng L, Zhu YF and Chen X: AMP-activated protein kinase (AMPK) activation is involved in chrysin-induced growth inhibition and apoptosis in cultured A549 lung cancer cells. Biochem Biophys Res Commun. 423:448–453. 2012. View Article : Google Scholar : PubMed/NCBI
33	Chiang CW, Kanies C, Kim KW, Fang WB, Parkhurst C, Xie M, Henry T and Yang E: Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Mol Cell Biol. 23:6350–6362. 2003. View Article : Google Scholar : PubMed/NCBI
34	Peso LD, González-García M, Page C, Herrera R and Nuñez G: Interleukin-3 induced phosphorylation of BAD through protein kinase Akt. Science. 278:687–689. 1997. View Article : Google Scholar : PubMed/NCBI
35	Jin YP, Fishbein MC, Said JW, Jindra PT, Rajalingam R, Rozengurt E and Reed EF: Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol. 65:291–302. 2004. View Article : Google Scholar : PubMed/NCBI
36	Wang H, Zhang Q, Wen Q, Zheng Y, Lazarovici P, Jiang H, Lin J and Zheng W: Proline-rich Akt substrate of 40kDa (PRAS40): A novel downstream target of PI3k/Akt signaling pathway. Cell Signal. 24:17–24. 2012. View Article : Google Scholar
37	Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999. View Article : Google Scholar : PubMed/NCBI